AUA: Prostate Cancer Risks, Overall Mortality, Significantly Higher Among Unmarried Men

Share this content:

(ChemotherapyAdvisor) – Unmarried men have a higher rate of prostate cancer-specific mortality than married men of similar age, race, stage, and tumor grade, according to a May 20 presentation at the American Urological Association Annual Meeting in Atlanta, GA.

“Marital status is an independent predictor of prostate cancer-specific mortality and overall mortality in men with prostate cancer,” noted Mark D. Tyson, MD, from Mayo Clinic, Phoenix, AZ, and colleagues, who evaluated the influence of marriage on survival outcomes in men diagnosed with prostate cancer.

They examined 115,922 cases of prostate cancer reported to the Surveillance Epidemiology and End Results (SEER) database between 1988 and 2003.

Of the men, 78% (n=91,490) were married and 22% (n=24,432) unmarried, which included those who were single, divorced, widowed, or separated. Married men were significantly younger (66.4 vs. 67.8 years), more likely to be white (85% vs. 76%), to present with lower tumor grades (68% well or moderately differentiated vs. 62%), and at earlier clinical stages (41% AJCC stage 1/2 vs. 37%; all P<0.0001). Duration of follow-up was 93.9 months for the married group and 75.2 months for the unmarried group.

Multivariate analysis found that unmarried men had a 40% increase in relative risk of prostate cancer-specific mortality, and a 51% increase in overall mortality (both P<0.0001); this difference was maintained after controlling for age, AJCC stage, tumor grade, and race. “Furthermore, the 5-year disease-specific survival rates for married men was 89.1% compared to 80.5% for unmarried men (P<0.0001),” they concluded.

Abstract (Insert “171” in the “Search by Publication Number”)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs